Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
Cerilliant
Cantor Fitzgerald
Citi
Chinese Patent Office
AstraZeneca
Healthtrust
Fuji
Covington

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,053,427

« Back to Dashboard

Which drugs does patent 8,053,427 protect, and when does it expire?

Patent 8,053,427 protects MIRVASO and is included in one NDA.

This patent has twenty-six patent family members in twenty-four countries.
Summary for Patent: 8,053,427
Title:Brimonidine gel composition
Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
Inventor(s): Buge; Jean-Christophe (Nice, FR), Nadau-Fourcade; Karine (Villeneuve-Loubet, FR), Meunier; Cyril (Mougins, FR)
Assignee: Galderma R&D SNC (Biot, FR)
Application Number:13/158,987
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Drugs Protected by US Patent 8,053,427

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,053,427

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,163,725 Gel compositions and methods of use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,053,427

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112013009578 ➤ Subscribe
China 103298451 ➤ Subscribe
Cyprus 1115683 ➤ Subscribe
Denmark 2444068 ➤ Subscribe
European Patent Office 2444068 ➤ Subscribe
European Patent Office 2629757 ➤ Subscribe
Spain 2498217 ➤ Subscribe
France 2966366 ➤ Subscribe
Croatia P20140811 ➤ Subscribe
Israel 225760 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
McKesson
Chubb
Daiichi Sankyo
Queensland Health
Deloitte
US Army
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot